Airsculpt Technologies (AIRS)

$4.74

+0.31

(+7%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $4.19
    $4.80
    $4.74
    downward going graph

    11.6%

    Downside

    Day's Volatility :12.71%

    Upside

    1.25%

    downward going graph
  • $3.21
    $9.18
    $4.74
    downward going graph

    32.28%

    Downside

    52 Weeks Volatility :65.03%

    Upside

    48.37%

    downward going graph

Returns

PeriodAirsculpt TechnologiesSector (Health Care)Index (Russel 2000)
3 Months
-16.11%
5.3%
0.0%
6 Months
-42.12%
6.3%
0.0%
1 Year
-44.24%
9.2%
0.0%
3 Years
-70.17%
13.1%
-19.9%

Highlights

Market Capitalization
263.7M
Book Value
$1.45
Earnings Per Share (EPS)
0.02
PE Ratio
229.0
Wall Street Target Price
6.0
Profit Margin
0.79%
Operating Margin TTM
23.14%
Return On Assets TTM
5.67%
Return On Equity TTM
1.97%
Revenue TTM
197.7M
Revenue Per Share TTM
3.47
Quarterly Revenue Growth YOY
3.9%
Gross Profit TTM
110.5M
EBITDA
29.4M
Diluted Eps TTM
0.02
Quarterly Earnings Growth YOY
2.0
EPS Estimate Current Year
0.24
EPS Estimate Next Year
0.31
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
0.07

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Airsculpt Technologies(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.58%

Current $4.74
Target $6.00

Company Financials

FY19Y/Y Change
Revenue
41.2M
-
Net Income
-5.1M
-
Net Profit Margin
-12.34%
-
FY20Y/Y Change
Revenue
62.8M
↑ 52.21%
Net Income
5.8M
↓ 213.03%
Net Profit Margin
9.16%
↑ 21.5%
FY21Y/Y Change
Revenue
133.3M
↑ 112.4%
Net Income
10.6M
↑ 83.5%
Net Profit Margin
7.91%
↓ 1.25%
FY22Y/Y Change
Revenue
168.8M
↑ 26.61%
Net Income
-14.7M
↓ 239.12%
Net Profit Margin
-8.7%
↓ 16.61%
FY23Y/Y Change
Revenue
195.9M
↑ 16.07%
Net Income
-4.5M
↓ 69.49%
Net Profit Margin
-2.29%
↑ 6.41%
Q4 FY22Q/Q Change
Revenue
40.7M
↑ 4.66%
Net Income
-7.2M
↓ 2.51%
Net Profit Margin
-17.67%
↑ 1.3%
Q1 FY23Q/Q Change
Revenue
45.8M
↑ 12.55%
Net Income
-14.0K
↓ 99.81%
Net Profit Margin
-0.03%
↑ 17.64%
Q2 FY23Q/Q Change
Revenue
55.7M
↑ 21.59%
Net Income
1.8M
↓ 12785.71%
Net Profit Margin
3.19%
↑ 3.22%
Q3 FY23Q/Q Change
Revenue
46.8M
↓ 16.0%
Net Income
-1.7M
↓ 193.86%
Net Profit Margin
-3.56%
↓ 6.75%
Q4 FY23Q/Q Change
Revenue
47.6M
↑ 1.74%
Net Income
-4.6M
↑ 174.39%
Net Profit Margin
-9.61%
↓ 6.05%
Q1 FY24Q/Q Change
Revenue
47.6M
↑ 0.03%
Net Income
6.0M
↓ 231.81%
Net Profit Margin
12.66%
↑ 22.27%
FY19Y/Y Change
Total Assets
171.5M
-
Total Liabilities
51.1M
-
FY20Y/Y Change
Total Assets
179.6M
↑ 4.73%
Total Liabilities
55.9M
↑ 9.44%
FY21Y/Y Change
Total Assets
200.6M
↑ 11.66%
Total Liabilities
117.0M
↑ 109.22%
FY22Y/Y Change
Total Assets
200.8M
↑ 0.1%
Total Liabilities
130.0M
↑ 11.08%
FY23Y/Y Change
Total Assets
213.6M
↑ 6.37%
Total Liabilities
129.6M
↓ 0.33%
Q4 FY22Q/Q Change
Total Assets
200.8M
↑ 3.53%
Total Liabilities
130.0M
↑ 7.04%
Q1 FY23Q/Q Change
Total Assets
209.5M
↑ 4.36%
Total Liabilities
134.3M
↑ 3.31%
Q2 FY23Q/Q Change
Total Assets
217.3M
↑ 3.71%
Total Liabilities
135.8M
↑ 1.13%
Q3 FY23Q/Q Change
Total Assets
204.1M
↓ 6.06%
Total Liabilities
119.9M
↓ 11.69%
Q4 FY23Q/Q Change
Total Assets
213.6M
↑ 4.62%
Total Liabilities
129.6M
↑ 8.03%
Q1 FY24Q/Q Change
Total Assets
202.7M
↓ 5.08%
Total Liabilities
119.2M
↓ 7.99%
FY19Y/Y Change
Operating Cash Flow
4.9M
-
Investing Cash Flow
-4.4M
-
Financing Cash Flow
-783.0K
-
FY20Y/Y Change
Operating Cash Flow
14.0M
↑ 182.64%
Investing Cash Flow
-3.7M
↓ 16.9%
Financing Cash Flow
-5.0M
↑ 540.74%
FY21Y/Y Change
Operating Cash Flow
26.6M
↑ 90.82%
Investing Cash Flow
-7.1M
↑ 92.9%
Financing Cash Flow
-4.5M
↓ 9.33%
FY22Y/Y Change
Operating Cash Flow
24.4M
↓ 8.21%
Investing Cash Flow
-12.9M
↑ 81.58%
Financing Cash Flow
-27.3M
↑ 499.19%
Q4 FY22Q/Q Change
Operating Cash Flow
6.6M
↑ 1918.24%
Investing Cash Flow
-2.2M
↓ 52.15%
Financing Cash Flow
-2.4M
↓ 89.62%
Q1 FY23Q/Q Change
Operating Cash Flow
6.2M
↓ 6.34%
Investing Cash Flow
-3.8M
↑ 73.8%
Financing Cash Flow
-737.0K
↓ 69.66%
Q2 FY23Q/Q Change
Operating Cash Flow
12.2M
↑ 96.75%
Investing Cash Flow
-2.2M
↓ 43.36%
Financing Cash Flow
-579.0K
↓ 21.44%

Technicals Summary

Sell

Neutral

Buy

Airsculpt Technologies is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Airsculpt Technologies
Airsculpt Technologies
21.23%
-42.12%
-44.24%
-70.17%
-70.17%
Fresenius Medical Care Ag
Fresenius Medical Care Ag
0.46%
0.26%
-26.34%
-51.93%
-48.92%
Hca Holdings, Inc.
Hca Holdings, Inc.
-4.68%
14.2%
14.1%
30.96%
131.31%
Tenet Healthcare Corp. 
Tenet Healthcare Corp. 
-0.83%
67.64%
75.45%
88.33%
667.79%
Universal Health Services Inc.
Universal Health Services Inc.
-4.63%
18.44%
22.82%
19.32%
36.24%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
-2.72%
34.72%
37.08%
16.04%
136.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Airsculpt Technologies
Airsculpt Technologies
229.0
229.0
NA
0.24
0.02
0.06
NA
1.45
Fresenius Medical Care Ag
Fresenius Medical Care Ag
21.88
21.88
0.39
1.5
0.05
0.03
0.03
47.4
Hca Holdings, Inc.
Hca Holdings, Inc.
16.08
16.08
1.44
20.98
0.85
0.11
0.01
-6.14
Tenet Healthcare Corp. 
Tenet Healthcare Corp. 
5.23
5.23
1.74
8.98
0.54
0.07
NA
35.35
Universal Health Services Inc.
Universal Health Services Inc.
15.36
15.36
1.87
13.79
0.13
0.06
0.0
93.48
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
15.64
15.64
1.16
9.32
0.43
0.06
NA
10.56
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Airsculpt Technologies
Airsculpt Technologies
Buy
$263.7M
-70.17%
229.0
0.79%
Fresenius Medical Care Ag
Fresenius Medical Care Ag
Hold
$11.6B
-48.92%
21.88
2.48%
Hca Holdings, Inc.
Hca Holdings, Inc.
Buy
$84.4B
131.31%
16.08
8.2%
Tenet Healthcare Corp. 
Tenet Healthcare Corp. 
Buy
$13.2B
667.79%
5.23
12.54%
Universal Health Services Inc.
Universal Health Services Inc.
Hold
$12.1B
36.24%
15.36
5.57%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
Hold
$12.1B
136.02%
15.64
6.61%

Insights on Airsculpt Technologies

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 46.79M → 47.62M (in $), with an average increase of 0.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.57M → 6.02M (in $), with an average increase of 175.9% per quarter

  • Vs THC

    In the last 1 year, Tenet Healthcare Corp.  has given 75.7% return, outperforming this stock by 122.6%

Institutional Holdings

  • Vesey Street Capital Partners, L.L.C.

    50.94%
  • SW Investment Management LLC

    7.45%
  • Balyasny Asset Management LLC

    1.53%
  • BlackRock Inc

    1.38%
  • Vanguard Group Inc

    1.00%
  • Geode Capital Management, LLC

    0.56%

Company Information

at elite body sculpture we focus on body contouring. using our minimally invasive and patented airsculpt® technology, our procedures are geared to make healing faster with less bruising and less trauma to the area being treated. our commitment is to provide the very best possible results for each patient, using the most up to date and advanced technology.

Organization
Airsculpt Technologies
Employees
346
CEO
Dr. Aaron J. Rollins M.D.
Industry
Healthcare

FAQs